Table 1.
The presence of parvovirus-specific IgG class antibodies in the patients and control group.
| Patients (n = 42) |
Control Group (n = 50) |
p Value | |
|---|---|---|---|
| n (%) | |||
| Total B19V IgG | 35 (83.33%) | 37 (74.0%) | 0.3194 |
| Total HBoV1–4 IgG | 26 (61.9%) | 29 (58.0%) | >0.9999 |
| Total hPARV4 IgG | 1 (2.38%) | 5 (10.0%) | 0.2141 |
| Without IgGs | 5 (11.9%) | 4 (8.0%) | 0.7270 |
| B19V IgG only | 11 (26.19%) | 15 (30.0%) | 0.8170 |
| HBoV 1–4 IgG only | 2 (4.76%) | 8 (16.0%) | 0.1035 |
| hPARV4 IgG only | 0 (0%) | 1 (2.0%) | >0.9999 |
| B19V + HBoV1–4 IgG | 23 (54.76%) | 18 (36.0%) | 0.0929 |
| B19V + hPARV4 IgG | 0 (0%) | 1 (2.0%) | >0.9999 |
| B19V + HBoV1–4 + hPARV4 IgG | 1 (2.38%) | 3 (6.0%) | 0.6225 |
n—number of cases; B19V—human parvovirus B19; HBoV1–4—human bocaviruses 1 to 4; hPARV4—human parvovirus 4; IgG—immunoglobulin G.